Director/PDMR Shareholding

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Connor

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.597

43,760

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2020-02-18

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms D Conrad

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Following the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan, Ms Conrad received a cash amount of approximately £152,000 (less applicable tax withholding) which is equal to the market value of the number of Ordinary Shares which would otherwise have been transferred to her.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.597

9,168

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2020-02-19

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr J Ford

b)

Position/status

SVP & General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

The sale of ADSs to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$43.544

2,454

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2020-02-18

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.597

16,122

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2020-02-18

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms S Jackson

b)

Position/status

SVP, Global Communications & CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.597

4,309

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2020-02-18

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Jackson

b)

Position/status

PCA of Ms S Jackson (SVP, Global Communications & CEO Office)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.597

1,111

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2020-02-18

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

The sale of ADSs to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$43.544

33,055

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2020-02-18

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Miels

b)

Position/status

President Global Pharmaceuticals

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.597

65,213

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2020-02-18

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.597

31,324

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2020-02-18

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Simard

b)

Position/status

President, Pharmaceuticals Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.597

4,309

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2020-02-18

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.597

21,650

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2020-02-18

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms D Waterhouse

b)

Position/status

CEO of ViiV Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.597

5,909

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2020-02-18

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms V Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.597

4,309

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2020-02-18

f)

Place of the transaction

London Stock Exchange (XLON)